{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:22Z","timestamp":1790217382234,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ajo.2018.09.039","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T05:37:09Z","timestamp":1539063429000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity"],"prefix":"10.1016","volume":"198","author":[{"given":"Tiffany A.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary H.","family":"Bodnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-9605","authenticated-orcid":false,"given":"Natalia F.","family":"Callaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira H.","family":"Schachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius M.","family":"Moshfeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ajo.2018.09.039_bib1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","article-title":"Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study","volume":"126","author":"Kong","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2018.09.039_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"3 Suppl","key":"10.1016\/j.ajo.2018.09.039_bib3","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.ajo.2018.09.039_bib4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2018.09.039_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Mart\u00ednez-Castellanos","year":"2013","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2018.09.039_bib6","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2018.09.039_bib7","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/archophthalmol.2010.145","article-title":"Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment","volume":"128","author":"Hoang","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2018.09.039_bib8","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2018.09.039_bib9","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","article-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","volume":"123","author":"Toy","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2018.09.039_bib10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.5301\/ejo.5000295","article-title":"Persistent plus disease after laser in retinopathy of prematurity with tetralogy of Fallot","volume":"23","author":"Paulus","year":"2013","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2018.09.039_bib11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2018.09.039_bib12","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"1","key":"10.1016\/j.ajo.2018.09.039_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1542\/peds.2012-2996","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"131","author":"Fierson","year":"2013","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.ajo.2018.09.039_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","article-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children","volume":"16","author":"Blair","year":"2012","journal-title":"J AAPOS"},{"issue":"11","key":"10.1016\/j.ajo.2018.09.039_bib15","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1167\/iovs.06-0152","article-title":"Optic disk size and optic disk-to-fovea distance in preterm and full-term infants","volume":"47","author":"De Silva","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.ajo.2018.09.039_bib16","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2018.09.039_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","article-title":"Retinal vascular development with 0.312\u00a0mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study","volume":"37","author":"Lorenz","year":"2017","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2018.09.039_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"10.1016\/j.ajo.2018.09.039_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"7","key":"10.1016\/j.ajo.2018.09.039_bib20","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/IAE.0b013e31820d3f70","article-title":"Management of avascular peripheral retina in older prematurely born infants","volume":"31","author":"Ho","year":"2011","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.ajo.2018.09.039_bib21","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0161-6420(01)00660-1","article-title":"Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears","volume":"108","author":"Kaiser","year":"2001","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2018.09.039_bib22","doi-asserted-by":"crossref","first-page":"e0149176","DOI":"10.1371\/journal.pone.0149176","article-title":"Peripheral retinal vascular patterns in patients with rhegmatogenous retinal detachment in Taiwan","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ajo.2018.09.039_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2018.09.039_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","article-title":"Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy","volume":"18","author":"Henaine-Berra","year":"2014","journal-title":"J AAPOS"},{"issue":"7","key":"10.1016\/j.ajo.2018.09.039_bib25","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1167\/iovs.08-1780","article-title":"Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease","volume":"49","author":"Hartnett","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2018.09.039_bib26","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1167\/iovs.06-0850","article-title":"Changes in pericytes and smooth muscle cells in the kitten model of retinopathy of prematurity: implications for plus disease","volume":"48","author":"Hughes","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.ajo.2018.09.039_bib27","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/eye.2017.18","article-title":"Characteristic clinical features associated with aggressive posterior retinopathy of prematurity","volume":"31","author":"Ahn","year":"2017","journal-title":"Eye"},{"issue":"5","key":"10.1016\/j.ajo.2018.09.039_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ceo.12280","article-title":"Prevalence and outcomes of laser treatment of aggressive posterior retinopathy of prematurity","volume":"42","author":"Gunn","year":"2014","journal-title":"Clin Experiment Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2018.09.039_bib29","doi-asserted-by":"crossref","first-page":"F174","DOI":"10.1136\/adc.2009.160366","article-title":"Is ethnicity a risk factor for severe retinopathy of prematurity?","volume":"95","author":"Aralikatti","year":"2010","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"8622","key":"10.1016\/j.ajo.2018.09.039_bib30","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0140-6736(88)90820-3","article-title":"Epidemiology of retinopathy of prematurity","volume":"2","author":"Ng","year":"1988","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ajo.2018.09.039_bib31","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/diabetes.51.4.1218","article-title":"Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in brown Norway and Sprague Dawley rats contributing to different susceptibilities to retinal neovascularization","volume":"51","author":"Gao","year":"2002","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ajo.2018.09.039_bib32","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"Garcia Gonzalez","year":"2018","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.ajo.2018.09.039_bib33","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.ophtha.2004.02.005","article-title":"Involution of threshold retinopathy of prematurity after diode laser photocoagulation","volume":"111","author":"Coats","year":"2004","journal-title":"Ophthalmology"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939418305816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939418305816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:39:19Z","timestamp":1757597959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939418305816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":33,"alternative-id":["S0002939418305816"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2018.09.039","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2018.09.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}